Altimmune (ALT) to Release Quarterly Earnings on Tuesday

Altimmune (NASDAQ:ALT) will issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The business had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 53.09% and a negative net margin of 24,778.97%. During the same quarter in the prior year, the company posted ($0.32) earnings per share. On average, analysts expect Altimmune to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Altimmune Stock Performance

Shares of NASDAQ:ALT traded up $0.09 during midday trading on Tuesday, hitting $6.88. The company’s stock had a trading volume of 1,193,854 shares, compared to its average volume of 3,766,829. The business’s 50 day simple moving average is $6.76 and its 200 day simple moving average is $6.85. The company has a market cap of $488.96 million, a P/E ratio of -4.19 and a beta of 0.09. Altimmune has a 12-month low of $2.32 and a 12-month high of $14.84.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ALT shares. Evercore ISI raised shares of Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. B. Riley reissued a “buy” rating and issued a $20.00 price target on shares of Altimmune in a research note on Monday, August 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Thursday, August 22nd. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $18.80.

Insider Activity

In other news, Director David Drutz sold 16,011 shares of the company’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $6.90, for a total value of $110,475.90. Following the completion of the transaction, the director now owns 41,958 shares in the company, valued at approximately $289,510.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.10% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.